Detalles de la búsqueda
1.
Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years.
Clin Infect Dis;
58(3): 413-22, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24145879
2.
Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents.
Clin Pharmacokinet;
62(10): 1445-1459, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37603217
3.
Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age.
AIDS;
35(9): 1413-1421, 2021 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33831904
4.
Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study.
J Pediatric Infect Dis Soc;
9(2): 159-165, 2020 Apr 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-30951600
5.
Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy.
Pediatr Infect Dis J;
28(3): 215-9, 2009 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-19209098
6.
Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors.
Antimicrob Agents Chemother;
52(9): 3276-83, 2008 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-18625762
7.
Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial.
Lancet HIV;
5(12): e715-e722, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30527329
8.
Development and Validation of the PREMM5 Model for Comprehensive Risk Assessment of Lynch Syndrome.
J Clin Oncol;
35(19): 2165-2172, 2017 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28489507
9.
Comparison of Prediction Models for Lynch Syndrome Among Individuals With Colorectal Cancer.
J Natl Cancer Inst;
108(2)2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26582061
10.
Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents: Forty-eight-week Results from IMPAACT P1093.
Pediatr Infect Dis J;
34(11): 1207-13, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26244832
11.
Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age.
J Pediatric Infect Dis Soc;
4(4): e76-83, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26582887
12.
Dynamics of the resting CD4(+) T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age.
AIDS;
26(12): 1483-90, 2012 Jul 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-22555165
13.
Long-term outcomes for HIV-infected infants less than 6 months of age at initiation of lopinavir/ritonavir combination antiretroviral therapy.
AIDS;
25(5): 643-9, 2011 Mar 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-21297419
14.
Associations of proinflammatory cytokine levels with lipid profiles, growth, and body composition in HIV-infected children initiating or changing antiretroviral therapy.
Pediatr Infect Dis J;
29(12): 1118-22, 2010 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-20631646
15.
Insulin-like growth factor-1 and lean body mass in HIV-infected children.
J Acquir Immune Defic Syndr;
48(4): 437-43, 2008 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-18614924
16.
Lipid and glucose alterations in HIV-infected children beginning or changing antiretroviral therapy.
Pediatrics;
122(1): e129-38, 2008 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-18519448
17.
Impact of nucleoside reverse transcriptase inhibitors on mitochondria in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy.
Antimicrob Agents Chemother;
51(12): 4236-42, 2007 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-17893156
18.
Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism.
J Acquir Immune Defic Syndr;
45(3): 280-5, 2007 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17356468
Resultados
1 -
18
de 18
1
Próxima >
>>